Life Sciences Archive » July, 2015

Life Sciences - July, 2015

301 articles

• USPTO Patent Guidance Has Attys Fearing Wave Of Rejections
• Covidien Urges Supreme Court To Hear 'Secret' Prior Art Row
• Taxation With Representation: Sullivan, Wachtell, MoFo
• Credit Union's Suit Could Open Up Banking For Pot Business
• Forest Labs Says Sex-Bias Plaintiffs Lack Evidence
• Gunderson Nabs Ex-DLA Partners To Boost Calif. Offices
• 10 IPOs Targeting $1.4B Ready To Rock 1st Week Of August
• Fed. Circ. Says Judge Got X-Ray Patent Wrong, Revives Suit
• 7th Circ. Refuses To Adopt Tighter Class Cert. Standard
• Medicare Does Not Cover Lab's Cancer Test, Judge Rules
• London Calling: On The Cusp Of A UK Biotech Revolution
• $400M Pfizer Class Action Deal Gets OK From Judge
• 7 Keys To Improving Your Direct Examination
• Nexium Judge Gives Rare Look Into Landmark Antitrust Trial
• Cephalon Can't Dodge Provigil Claims In FCA Off-Label Suit
• No New Trial For Drug Buyers In Nexium Pay-For-Delay Suit
• Rise Of Crossover Rounds: More Biotechs Eye Late-Stage Cash
• Bayer, Merck Hit With More Suits Over Avelox Nerve Damage
• USPTO Posts Update On Alice, Mayo, Myriad Rules
• Novartis Looks To Kill Gleevec Antitrust Suit
• AbbVie Says Chancery Rightly Axed Suit Over Failed Inversion
• NuVasive Inks $14M FCA Deal Over Kickbacks, Off-Label Uses
• Bio-Rad Says Former GC Was Fired For 'Abusive' Conduct
• Corporate Tax Code Needs Reform, Senate Panel Hears
• Utah High Court Sends Amnesiac Atty's Fee Dispute To Jury
• Prosecution Of Off-Label Speech In A Post-Caronia World
• Final Thalidomide Claim Is Time-Barred, GSK Tells 3rd. Circ.
• Actavis Blasts USPTO Decision In Opana Row
• Medicare Contractors Overpaid $36M For Drugs, Audit Finds
• PTAB To Scrutinize Xyrem Patents In Inter Partes Review
• Novartis Spins Off 3 Drugs To New UK Biopharma Company
• US Seeks Criminal Contempt Over Herbal Supplement Store
• European Commission OKs Mylan's Hostile Perrigo Takeover
• Celgene Wants Sanctions For 'Abusive' AIA Review Petition
• Why UK Backed Off From Loyalty Rebate Abuse Probe
• J&J, Janssen Face Risperdal Suit From Cherokee Nation
• The Top Product Liability Cases Of 2015: Midyear Report
• Janssen Hit With Another Levaquin Nerve Damage Suit
• Caris Employees Get $16.3M After Co. Sharply Devalued Stock
• Herbalife Again Escapes Shareholder Class Action
• Glenmark Infringed Bayer's Finacea Patent, Judge Rules
• Ex-Teva Exec. Blames Firing On FCPA Probe Cooperation
• Robbins Geller Named Lead Counsel In Glaucoma Drug Row
• Purdue Loses Reconsideration Bid In Chicago's Painkiller Suit
• Ohio Doc Must Face Claims In Meningitis MDL, Court Rules
• House OKs Congressional Review For Major Regulations
• Contact Lens Cos. Call Utah Pricing Law Unconstitutional
• Locke Lord Booted From Supplement False Ad Class Action
• Hikma To Pay $2.7B For Boehringer US Unit
• 4th Circ. Won't Reconsider GNC Win In False Ad Suit
• Cancer Biotech NantKwest's $207M IPO Trumps Expectations
• Teva Tells Fed. Circ. AstraZeneca Suit Belongs In Delaware
• FDA Floats Plan For Measuring Drugmaker Quality
• NJ Pharma Co. Revives Lupus Product Row With FDA
• Sullivan Scores For New Client Teva In $40.5B Allergan Deal
• Provigil Buyers Win Class Cert. In Pay-For-Delay Fight
• GSK Pushes 3rd Circ. To Rehear Lamictal Pay-For-Delay Suit
• Drug Cos. Say Rulings Don't Boost Actos Pay-For-Delay Suit
• Manufacturers Seek Robust IP, Investment Rules In TPP
• Shire Allowed Access To Confidential Info In Adderall Row
• 3rd Circ. Won't Rethink Girardi Keese Avandia Fee
• FTC Asks AbbVie, Others For Deal Docs In Pay-For-Delay Suit
• Anthem Sued Again Over Gilead Hep C Drug Coverage
• Teva Inks $40.5B Deal For Allergan Generics Unit
• Law360's Trial Aces Make Winning Look Easy
• Medtronic Asks Justices To Weigh Patent Fight Under Commil
• Biolitec Takes $70M Contempt Ruling To High Court
• VA Small Biz Contract Lacked Sufficient Research, GAO Says
• Convicted McDonnell Asks 4th Circ. For En Banc Rehearing
• FDA Faces Backlash On Drug Compounding Limits
• Knobbe Martens Blasts DQ Bid In Patent Dispute
• Hundreds Of NJ Suits Involving New Accutane Label Tossed
• Judge Halts, Mostly Tosses Whole Foods Homeopathy Suit
• Bayer Can't Nix Claims In Mirena IUD Blindness Lawsuit
• No Ban On Utah Contact Lens Pricing, 10th Circ. Hears
• 11 Cos. Set Sights On $2.4B In End-Of-July IPO Rush
• Sports Supplement Co. Hits Rival With False Ad Suit
• Medtronic Can't Escape Patent Suit, Texas Judge Rules
• Bristol-Meyers, Pfizer Sued Over Blood Thinner Death
• Rimon Snags Ex-Gunderson Deal-Maker In San Francisco
• Senators Seek To Block Feds From Punishing Pot Banks
• The Contentious Biosimilar Nonproprietary Naming Debate
• REBUTTAL: The Problem With 3rd-Party Litigation Financing
• Eli Lilly Slams 'Startling' Teva Brief In Alimta Patent Fight
• Juror's Google Search Triggers New Tylenol Death Trial
• Lupin Shells Out $880M For NJ-Based Pharma Co.
• Mylan Foundation Moves To Thwart Teva $40B Hostile Bid
• Novo Nordisk Objects To Expert In ITC Drug Patent Row
• Biotech Says Solomon Isn't Owed $3.7M For AstraZeneca Deal
• Biotech Sues Patent Management Firm For Overcharging
• GSK Faces Wave Of Zofran Birth Defect Suits
• Baylor Sued By Research Doctor Over Patent Royalties
• Pfizer Patent Not Indefinite In Sandoz IP Row, Judge Says
• Firm Must Pay MDL Fee After Avandia State Settlement
• Endo's Opana Patent Survives AIA Challenge By Amneal
• Steris Corp. Accused Of Selling Tainted Goods To Gov't
• Gray Reed Knocks Medtronic's Patent Suit 'Smear Campaign'
• Recent Lessons In D&O Fee Advancement And Indemnification
• Judge Won't DQ Skadden In Ex-Oriole Insider Trading Case
• Mylan Investors Slam Tax Inversion As Anti-Teva Ploy
• Teva Escapes Merck's Patent Suit Over Generic Nasonex
• Watson Moves To Undo Amarin's Exclusivity Win Over FDA
• Shire Rehearing Bid Parrots Rejected Claims, Fed. Circ. Told
• Herbalife Seeks Discovery To Identify Negative Tweeter
• Teva, Boehringer Get Quick Appeal In Pay-For-Delay MDL
• Eli Lilly Dodges 2nd Cymbalta Label Class Cert. Bid
• How To Become The Highest-Paid Partner At Your Firm
• Medtronic Seeks $6M In Fees In Long-Running Patent Case
• Hughes Hubbard Adds Ex-Kenyon Atty To NY Office's IP Group
• Gibson Dunn Guides St. Jude In $3.4B Deal For Thoratec
• Informing The Artisan: Reasonable Certainty In Patent Claims
• Ex Ante Vs. Ex Post: Janis Joplin's Yearbook Revisited
• Receptos Investor Sues To Block Celgene's $7.2B Buyout
• 5 Takeaways After Fed. Circ. Amgen-Sandoz Ruling
• Cephalon Can't Ditch FCA Claims In Off-Label Marketing Suit
• Amgen, Sandoz Both Winners And Losers At Federal Circuit
• SAC Beats Investors' Privilege Claims In Insider Trading Suit
• Chancery Tosses Claims Over Abbott Labs' AbbVie Spinoff
• Pfizer Gets Partial Win In Sandoz Generic Bladder Drug Row
• Deals Rumor Mill: Thoratec, Qualcomm, Nokia Here
• FTC Asks For Review Of AbbVie Pay-For-Delay Ruling
• Zoloft MDL Plaintiffs Agree To Pull Birth Defect Reports
• Lupin To Take Fight Over Pay-For-Delay Probe To 4th Circ.
• Patheon Wins Fees For Doc Fight In Procaps Merger Suit
• Horizon Pharma Raises Offer For Depomed Takeover
• SIGA Trustee Fights $700K In Executive Bonuses
• Gray Reed Says Medtronic's DQ Bid Can't Delay Patent Case
• DLA Piper Snags Ex-Cooley M&A Pro For Bay Area Team
• Fed. Circ. Amgen-Sandoz Ruling Extends Biologics Exclusivity
• Ensure Drinkers Hope Doctors' Notes Can Cure Class' Flaws
• Chicago Fights For Clarity In Drug Marketing Suit
• Atty Says False Ad Client's Residency Doesn't Merit Sanction
• Eli Lilly Can't Shake Prozac Heart Birth Defect Suit
• Alzheimer's Biotech Targets $125M IPO
• Reed Smith Adds India And Outsourcing Expert In NY
• Biolitec Tells 1st Circ. To Nix $70M Contempt Order
• Maquet Accused Of Retaliation By Ex-Compliance Exec
• Retailers' Claims Trimmed In Lidoderm Pay-For-Delay Case
• Stradley Ronon Nabs Ex-McCarter & English Litigation Pro
• Mayer Brown Nabs FDA Expert From Jones Day In DC
• Gowlings Adds IP Atty, Patent Agent As Vancouver Partner
• Procuring Personalized Medicine Patents In US Vs. Europe
• Takeda Ruling On Expert Standards To Ripple Beyond Actos
• Becton Sued For Squeezing Out Rivals With Safer Syringes
• CVS Gets OK For $7.4M Deal In Pharmacist OT Class Actions
• 6 IPOs Eye $1.04B In Coming Week
• Fed. Circ. Affirms Nixing Of Columbia's DNA Patent Claims
• Kirkland Warns Of Conflicts 'Sea Change' In Mylan Row
• Mylan Can Face Hatch-Waxman Suit In Del., Fed. Circ. Hears
• Big Pharma's TPP Protections For Biologics Face New Attacks
• Girardi Keese Asks Full 3rd Circ. To Review Avandia Fee Fight
• Inside FDA Regulation Of Antibody Drug Conjugates
• Pharma Lobby Wants Some Patents Exempt From AIA Review
• Ex-Reckitt Exec's Firing Case Can Proceed In NJ, Judge Says
• Alere Draws Up $220M In Deals To Beef Up Diagnostics Biz
• Endo Whistleblower Gets 24% Cut Of $140M FCA Deal
• $6M Takeda Verdict Reinstated In 1st Actos Cancer Trial
• Lowenstein Boosts White Collar Practice With Merck Counsel
• A New Look At An Old Medical Device Warranty Safe Harbor
• CR Bard Gets 1 of 2 Claims Tossed In Stent Patent Battle
• Lab Asks For Relief From Drugmaker's $3M Damages Claim
• Fed. Circ. Won't Vacate $2.25M Verdict In Argentum IP Row
• Inside The Recent Surge In Cancer Biotech IPOs
• Pfizer Says Zoloft Plaintiffs Stirring 'False Emergency'
• 3 Takeaways From FDA's Branded Drug User Fee Workshop
• House Approves Medicare Assisted Speech, Home Care Bills
• OpenGate Sanctioned In Thermo Fisher Fraud Suit
• NJ Expands Employer Liability In Ethicon Whistleblower Case
• OPINION: Litigation Finance Can Help Break The Glass Ceiling
• Bayer's Flanax Claim 'Distorts' Lanham Act, 4th Circ. Told
• McKesson Can Appeal Darvocet Remand Decision: Judge
• WilmerHale Nabs Ex-McDermott Patent Pro In LA
• Zoloft Plaintiffs Seek Pfizer's Contacts With Study Authors
• Bayer MDL Firms Certified As A Class Of Their Own
• Gay Blood Donation Policy Is Discriminatory, Lawmakers Say
• Liberty Medical Estate Gets Nod For Ch. 11 Plan
• WL Gore Asks High Court To Take On $1B Patent Case
• Lawmakers Train Sights On Part D Insurers Over Billing Fraud
• PTAB Mostly Rejects Lupin's AIA Review Of HIV Drug Patent
• LabCorp Keeps OT Suit In Calif. Federal Court
• Proskauer Advises Celgene In $7.2B Receptos Acquisition
• Consumer Groups Urge FTC To Block Teva's Hostile Mylan Bid
• The Biggest Calif. Court Decisions So Far In 2015
• Cooley Boosts NY Capital Markets Team With Ex-Skadden Atty
• Pfizer Moves To Quell EU Concerns On $17B Hospira Deal
• A 1st Look At PTAB's Plan For Overlapping Proceedings
• Abbott Board Seeks To Nix Suit From Spinoff's Shareholders
• Medtronic's DQ Attempt Is A 'Tactical Ploy,' Gray Reed Says
• Sanofi-Aventis Shakes FCA Suit Over Lovenox
• 5 Takeaways From FDA's Medical Device User Fee Workshop
• Avalanche Hit With 2nd Stock Drop Suit Over Eye Drug Study
• Drug Co. Celladon Faces Stock Drop Suit After CEO's Exit
• Merck Withholding Pay Data In Sex Bias Suit, Judge Told
• Lincare Dodges Bulk Of FCA Suit Over Medicare Marketing
• ANI Pharma Nabs $25M Teva Generic Drug Portfolio
• The FDA's Track And Trace Enforcement Delay: Stay Alert
• Senate Bill Would Ease Bank Access For Legal Pot Shops
• Plaintiffs Can Submit New Evidence In Scotts Bird Food Case
• DOJ's Maligned Integrity Unit Returns To Form With Big Win
• FTC Chair Says $1B Cephalon Deal Puts Cos. On Notice
• Idenix Investors Blame $12M Loss On Unclaimed-Stock Seizure
• 8 IPOs Set Sights On $600M In Coming Week
• Merck Says Bid To Amend Vioxx Investor Suit Is Too Late
• AbbVie, Teva Can't Make Niaspan Buyers Give Up Sales Data
• Endo's AMS Unit Settles More Than 100 Vaginal Mesh Suits
• FTC Gets Shot At Reviving AbbVie Pay-For-Delay Claims
• Avalanche Hit With Stock Drop Suit Over Eye Drug Study
• Haynes And Boone Nabs 2 IP Attys For Hatch-Waxman Group
• House Passes Sweeping 21st Century Cures Act
• FDA Toughens Stance On OTC, Prescription Pain Relievers
• Ex-Va. Gov. Loses Appeal Of Corruption Conviction
• A Possible Solution To Europe's Pharma Financing Problem
• Biogen Wants Kyle Bass To Give Up Financial Docs At PTAB
• San Jose Sues Monsanto, Pfizer Over PCBs
• 9th Circ.'s FCA Ruling To Spark More Whistleblower Fights
• Depomed Patents Challenged By Purdue Survive AIA Review
• Obama Troubled With 21st Century Cures Act Funding
• SEC Settles With 2 In Pot Stock Pump-And-Dump Case
• 4th Circ. Raises Bar For False Ad Plaintiffs In GNC Ruling
• 4 FCA Suits Allege Biogen Paid Kickbacks To Prescribers
• Norton Rose Nabs Ex-Sandoz North America GC
• AstraZeneca Divests Gastrointestinal Drug For $215M
• Fenwick Nabs Ex-Dechert Life Sciences Pro For IP Practice
• Norton Rose Fulbright Lures IP Atty From Allen & Overy
• Marijuana Dispensary Can't Deduct Biz Costs From Taxes
• CORRECTED: Jury Finds Boston Scientific Infringed Stent Patent
• NJ Is No Exception To The Learned Intermediary Doctrine
• How To Improve Drafting Language In Chemical Arts Patents
• Calif. High Court Won't Rehear Cipro Pay-For-Delay Ruling More
• Nexsen Pruet Adds Ex-Ward & Smith IP Atty
• SC Court Shaves $12M Off Risperdal Fine Against J&J Unit
• Eli Lilly Fights Plaintiffs' Expert Testimony In Cymbalta Suit
• Nature's Way Ginkgo Pills Don't Boost Memory, Suit Claims
• AstraZeneca Escapes Nexium False Ad Suit
• Texas Judge Tells Remoxy Plaintiffs To Refile Class Action
• FTC Ends Memory Pill False Ad Suit For $1.4M
• Cubist Pushes Fed. Circ. To Revive MRSA Drug Patents
• Kirkland Trying To Dupe Court In DQ Row, Mylan Says
• Canada's Gowlings To Merge With UK's Wragge Lawrence
• Biotech Says Solomon Wasn't Involved In AstraZeneca Deal
• 3rd Circuit To Link Up Effexor, Lipitor Pay-For-Delay Appeals
• New Bill Expanding Telehealth Coverage Gets Industry Support
• Teva, Mylan And The Impact Of 'Foreign' On HSR Analysis
• Pharma Co. CorMedix Faces Investor Suit After Stock Drop
• Insurer Knew Of Suit Years Before It Claims It Did, Court Told
• Omnicare, DOJ Strike Deal In Abbott Labs Kickback Suits
• Wash. Court Affirms Intuitive Win In Surgery Death Suit
• Medical Device Co. Pushes FCC For Ultra-Wideband Waiver
• Judge Grills Amarin, FDA Over Off-Label Promo Statements
• FDA Must Handle Politics Over Female Libido Drug, Docs Say
• En Banc 9th Circ. Loosens FCA's Original Source Requirement
• Judge Ices Zoloft MDL Hearing Over Potential Study Error
• BMS Sues Merck As Soon As USPTO Grants Cancer Patent
• Health Care Litigator Joins Seyfarth Shaw In Houston
• Horizon Pharma Makes $3B Hostile Bid For Depomed
• Endo, Impax Look To Nix Opana Pay-For-Delay Suits
• AstraZeneca, Cephalon Pay $54M To End Medicaid Rebate Row
• Fee Row In Bayer GMO Class Action Can Proceed, Judge Says
• Drug Cos. Fight Chicago's Clarification Bid After Dismissals
• Allergan To Pay $125M For Dry Eye Medical Device Co.
• AbbVie Says Reconsideration Not Needed In FTC Row
• Sheppard Mullin Adds Ex-Loeb & Loeb Corporate Atty
• Life Sciences Cases To Watch In The 2nd Half Of 2015
• Deals Rumor Mill: Teva, Mylan, Philip Morris, China Network
• FTC, Fla. AG Ask Judge To Stop Lifewatch Robocalls
• 5 Firms Top $300B In Deals During 1st Half Of 2015 M&A Boom
• How To Pitch A Pharmaceutical Company
• Knobbe Martens Twisting Facts In DQ Row, Court Told
• Shire Says Fed. Circ. Misapplied Teva Deference Standard
• Gould & Ratner Nabs Loeb & Loeb Atty To Head Its IP Group
• FDA Warns Online Drug Buyers Of Fake Generic Valium
• White House Orders Updated GMO Rules Amid Criticism
• Georgia AG Wades Into Mesh Implant Appeal In 4th Circ.
• Health Cases To Watch In The 2nd Half Of 2015
• VC-Backed Natera Beats Expectations With $180M IPO
• J&J Beats Bid For New Trial In Philly Risperdal Case
• Girardi Keese Can't Avoid Recovery Sharing In Avandia Suits
• Daiichi Sankyo Loses Patent Term Adjustment Challenge
• Brand Battles: Bayer, Philips, HBO, Red Bull
• Fla. Jury Clears IP Firm Of Malpractice In Legal Fees Flap
• The Biggest Pa. Court Decisions Of 2015: Midyear Report
• FTC Asks Court To Review AbbVie Pay-For-Delay Dismissal
• Regulators Are Cracking Down On Drug Disposal
• Amarin Ducks Securities Action Over Vascepa Denial
• Fed. Circ. Wipes Out Medicines Co.'s Angiomax Patents
• Judge Nixes Lupin Pay-For-Delay Suit Against Alaska AG
• M&A Boom Soars To Highest First-Half Clip In 8 Years
• Swiss Pregnancy Tests Deliberately Misleading, Judge Rules
• Teva Tells DC Circ. Ranbaxy Deserved Drug Revocation
• FDA Reviewing Codeine Cough Medicine Safety For Children
• 1 Firm Tops June IPO Activity As Volume Hits New Heights
• Magistrate Urges Dismissal Of Merck's Generic Nasonex Suit
• Kirkland Guides Madison Dearborn On $715M Rehab Biz Buy
• Pfizer Says Plaintiffs Are Rehashing Nixed Zoloft Testimony
• Xellia Found To Infringe Merck Anti-Fungal Med Patent
• Skadden Not Conflicted In Insider Trading Case, Court Told
• Former Pfizer Compliance Attorney Joins Morgan Lewis
• Eli Lilly Hit With IP Suit Over Cialis Use
• Life Tech Takes Gene Testing Patent Loss To High Court
• FDA Targets Unapproved Ear Drops After Infant Death
• An 'Exceptional Case' One Year After Octane: Part 2